- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00555152
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine whether lapatinib (lapatinib ditosylate) therapy at the dose of 1000 mg results in a statistically significantly lower rate of proliferation in ductal carcinoma in situ (DCIS) breast cancer cells as measured by Ki67 when compared to placebo.
II. Determine the toxicity profile and frequency of adverse events in women with DCIS breast cancer taking lapatinib at 1000 mg as compared to women taking placebo.
SECONDARY OBJECTIVES:
I. Determine whether lapatinib treatment affects the incidence of DCIS seen at the time of surgical excision.
II. Determine whether treatment with lapatinib will modulate breast tissue histology or the expression of specific biomarkers in normal and DCIS breast cancer cells.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive lapatinib ditosylate orally (PO) once daily (QD) for 2-6 weeks until the time of surgery.
ARM II: Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
After completion of study treatment, patients are followed for 4-5 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants must be premenopausal or postmenopausal
- Participants must have a diagnosis of ductal carcinoma in situ made by core needle biopsy
- The DCIS cells must have high expression of human epidermal growth factor receptor 2 (erbB2) (3+ by immunohistochemical staining or amplification by fluorescence in situ hybridization [FISH]), and/or have detectable expression of epidermal growth factor receptor (EGFR) (1+ or more by immunohistochemical staining)
- All participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
- Individuals with a diagnosis of breast cancer, non-melanoma skin cancer, cervical cancer in situ, or early bladder cancer are eligible if they have not been treated with chemotherapy, biological therapy, or breast radiotherapy to the breast currently affected by DCIS within one year; in addition, individuals with a diagnosis of breast cancer may not have used tamoxifen, raloxifene, or other antiestrogen compounds within three months of study day 1
- If subjects are of reproductive potential, they must agree to use a reliable contraceptive method or be sexually abstinent; subjects must fulfill these conditions beginning at the time of starting study medications and ending one month after study termination
- Negative serum pregnancy test (beta-human chorionic gonadotropin [HCG]) at baseline (within 30 days of day 0) for women of child bearing potential
- Serum creatinine =< 1.5 times the institution?s upper limit of normal
- Total bilirubin =< 1.5 times the institution's upper limits of normal
- Serum glutamic oxaloacetic transaminase (SGOT) =< 1.5 times the institution's upper limits of normal
- Alkaline phosphatase =< 1.5 times the institution's upper limits of normal
- Albumin =< 1.5 times the institution's upper limits of normal
- White blood cells (WBC) > 4.0 k/uL
- Platelet count > 100,000/uL
- Hematocrit of > 30%
- Cardiac ejection fraction within normal limits for the institution by multi gated acquisition scan (MUGA) scan or normal cardiac ultrasound (defined as within the upper limit of normal [ULN] for the institution)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
- Willingness to refrain from donating blood to others during the study
Exclusion Criteria:
- Individuals are ineligible if they have either active cancer or a prior history of malignancies other than (e.g., breast cancer, skin cancer [basal or squamous cell carcinoma], cervical cancer in situ, or early bladder cancer [preinvasive transitional cell carcinoma of the bladder]) within the past five years
- Participants are ineligible if they are currently being treated with tamoxifen, raloxifene, or with aromatase inhibitors (letrozole, anastrozole, exemestane)
- Individuals are ineligible if they have received chemotherapy, biological therapy (e.g., Herceptin), or radiotherapy for the treatment of any cancer within 1 year or if they have received tamoxifen, raloxifene, letrozole, anastrozole, or exemestane therapy within 3 months of study day 1
- Individuals currently receiving anticoagulation therapy (e.g., Coumadin) are ineligible
- Blood urea nitrogen [BUN] > 1.5 x ULN or
- Creatinine [Cr] > 1.5 x ULN
- SGOT > 1.5 x ULN
- Serum glutamate pyruvate transaminase (SGPT) > 1.5 x ULN
- Alkaline phosphatase > 1.5 x ULN
- Bilirubin > 1.5x ULN
- Individuals who are currently participating in a study of an investigational drug
- Pregnancy, lactation or unwillingness to use a reliable contraceptive method in women of childbearing potential
- Severe underlying chronic illness or disease, such as uncontrolled diabetes
- Individuals with known congestive heart disease or previous myocardial infarction are ineligible
- Patients taking any prohibited medications
- Individuals with hypokalemia or hypomagnesemia are ineligible unless these conditions are corrected to within normal limits before starting drug
- Individuals with congenital long QT syndrome or baseline QTcF intervals > 480 msec on electrocardiogram (EKG)
- Individuals taking anti-arrhythmics, beta blockers, or other medications that may lead to QT prolongation
- Individuals who have received a cumulative dose of anthracycline therapy greater than 500 mg/m^2 are ineligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (lapatinib ditosylate)
Patients receive lapatinib ditosylate PO once QD for 2-6 weeks until the time of surgery.
|
Correlative studies
Given PO
Other Names:
|
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO QD for 2-6 weeks until the time of surgery.
|
Correlative studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proliferation (Ki67 IHC) in Ductal Breast Carcinoma In Situ (DCIS)
Time Frame: 2-6 weeks from baseline to surgery, up to 6 weeks
|
Reduction in percent of Ki67 positive cells at surgery compared to baseline as a function of treatment.
Analysis of the primary treatment comparison will be based on a two sample t-test comparing change in log-transformed Ki67% for placebo and treated subjects.
P-values of 0.05 will be considered significant.
Proliferation will be assessed by immunohistochemical (IHC) staining for Ki67, and the change in percentage of Ki67 positive cells will be compared in lapatinib-treated samples versus placebo.
|
2-6 weeks from baseline to surgery, up to 6 weeks
|
Incidence of Adverse Events Graded According to the National Cancer Institute (NCI) Common Terminology Criteria (CTCAE) Version 3.0
Time Frame: From baseline to 4-5 weeks after surgery
|
Toxicity profile summarized reflects incidence by number of participants affected with adverse events by Maximum Grade 1 to 3, additional adverse event according to the NCI CTCAE version 3.0 reported in Adverse Event section results.
|
From baseline to 4-5 weeks after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Ductal Carcinoma in Situ Remaining at Resection
Time Frame: 2-6 weeks from baseline to surgery, up to 6 weeks
|
Number of participants with DCIS incidence on surgical excision.
Differences in histologic response (disappearance of DCIS) will be evaluated using Fisher's exact test.
Correlation analysis and linear models will be used to evaluate associations among marker values at baseline and among changes in marker values and treatment.
All statistical tests will be two-sided.
|
2-6 weeks from baseline to surgery, up to 6 weeks
|
Biomarker Analysis of Proliferation Markers
Time Frame: 2-6 weeks from baseline to surgery, Up to 6 weeks
|
Correlation analysis and linear models will be used to evaluate associations among marker values at baseline and among changes in marker values and treatment.
All statistical tests will be two-sided.
|
2-6 weeks from baseline to surgery, Up to 6 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Powel Brown, M.D. Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma, Ductal
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Breast Carcinoma In Situ
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Ductal, Breast
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Lapatinib
Other Study ID Numbers
- NCI-2009-00875 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA016672 (U.S. NIH Grant/Contract)
- 2008-0086
- NCT00570453
- CDR0000573719
- H-19895
- P50CA058183 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2/Neu Positive
-
Krankenhaus NordwestTerminatedHer2/Neu Positive Advanced Solid TumorsGermany
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
City of Hope Medical CenterGlaxoSmithKline; NovartisActive, not recruitingBreast Neoplasms | HER2/Neu Positive | Geriatric Health ServicesUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingInvasive Breast Carcinoma | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor PositiveUnited States
-
National Cancer Institute (NCI)WithdrawnEstrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Stage IV Breast Cancer AJCC v6 and v7
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyTerminatedBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2/Neu-positive Breast CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor PositiveUnited States
-
Memorial Sloan Kettering Cancer CenterCompletedHER2-positive Carcinoma | HER2-positive Primary MalignancyUnited States
-
University of NebraskaNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone... and other conditionsUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States